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Abstract:  Corneal  integrity  is  critical  for  vision.  Corneal  wounds  frequently  heal  with 
scarring  that  impairs  vision.  Recently,  human  umbilical  cord  mesenchymal  stem  cells  
(cord stem cells) have been investigated for tissue engineering and therapy due to their 
availability  and  differentiation  potential.  In  this  study,  we  used  cord  stem  cells  in  a  
3-dimensional (3D) stroma-like model to observe extracellular matrix organization, with 
human corneal fibroblasts acting as a control. For 4 weeks, the cells were stimulated with a 
stable Vitamin C (VitC) derivative ±TGF-1. After 4 weeks, the mean thickness of the 
constructs was ~30 m; however, cord stem cell constructs had 50% less cells per unit 
volume, indicating the formation of a dense matrix. We found minimal change in decorin 
and  lumican  mRNA,  and  a  significant  increase  in  perlecan  mRNA  in  the  presence  of  
TGF-1.  Keratocan  on  the  other  hand  decreased  with  TGF-1  in  both  cell  lineages.  
With  both  cell  types,  the  constructs  possessed  aligned  collagen  fibrils  and  associated 
glycosaminoglycans.  Fibril  diameters  did  not  change  with  TGF-1  stimulation  or  cell 
lineage; however, highly sulfated glycosaminoglycans associated with the collagen fibrils 
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significantly  increased  with  TGF-1.  Overall,  we  have  shown  that  cord  stem  cells  can 
secrete their own extracellular matrix and promote the deposition and sulfation of various 
proteoglycans. Furthermore, these cells are at least comparable to commonly used corneal 
fibroblasts and present an alternative for the 3D in vitro tissue engineered model. 
Keywords: stem cells; extracellular matrix; cornea; glycosaminoglycans 
 
1. Introduction 
One of the main threats for the human eye following injury or disease is the development of a scar, 
which can compromise a person’s vision and even lead to blindness. Treatment options are generally 
limited  to  corneal  transplants,  although  several  investigations  have  examined  the  potential  use  of 
biomaterials  as  a  corneal  substitute.  Recently,  studies  have  considered  the  possibility  of  stem  cell 
transplantation. Stem cells have the potential to repair damaged organs and tissues, and they are also 
known for their unique intrinsic characteristics, which enable them to control cell replacement during 
homeostasis and tissue repair [1]. The characteristics of stem cells make them highly attractive for use 
in tissue engineering and artificial in vitro applications. 
To date, the most commonly used source of adult mesenchymal stem cells (MSCs) is the bone 
marrow  (BMSCs);  however,  MSCs  are  also  found  in  adipose  tissue,  blood,  dermis  and  fat.  
Researchers [2,3] have shown that BMSCs contribute to the regeneration of a variety of tissues, such 
as bone, cartilage, muscle, ligament, tendon, adipose and stroma [2,3]. Unfortunately, there are a few 
draw backs to BMSCs that are leading scientists to seek alternative stem cell sources: (1) BMSCs are 
found  in  low  numbers  in  tissues,  (2)  Tissue  and  organ  availability  is  limited  and  (3)  BMSCs 
differentiation rate decreases over time [4]. In recent years, umbilical cord blood stem cells (cord stem 
cells) have been presented as an alternative to BMSCs. Cord stem cells are extracted from either cord 
blood or the Wharton’s jelly of umbilical cords through enzyme digestion [5] and have a number of 
critical  advantages  over  other  MSCs:  (1)  the  tissue  is  routinely  discarded;  therefore,  the  tissue  is 
available for cord stem cell extraction; (2) the collection process of the tissue is non-invasive; and  
(3) there is no donor risk to an organ or tissue. 
In  the  cornea,  the  three  major  cellular  layers  (epithelium,  endothelium  and  stroma)  may  need 
restoration  following  injury.  Currently,  tissue  engineered  corneal  epithelial  cell  sheets  are  used 
clinically in patients with total limbal stem cell deficiencies [6-9], and corneal endothelial cell sheets 
have, in fact, successfully restored corneal transparency in animal models [10-13]. However, none of 
the  cell-based  tissue  engineered  corneal  stromal  substitutes  have  been  clinically  feasible,  although 
several kinds of tissue engineered corneal stroma have been reported [14]. Recently, our group has 
shown that human corneal fibroblasts retain the ability to deposit a complex extracellular matrix when 
stimulated with Vitamin C (VitC), and this ability is enhanced with the presence of specific growth 
factors, which drive the construct toward an in vitro stroma-like model. In this study, we investigated 
the ability of the cord stem cells to stratify and deposit an organized and functional matrix that is 
comparable  to that  deposited  by  corneal  fibroblasts. Their  ability  to organize  and  align  their  own 
extracellular matrix is potentially crucial for their use as a corneal biomaterial.  J. Funct. Biomater. 2011, 2                             
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The major proteins of the stromal matrix include the collagens and the proteoglycans with their 
associated glycosaminoglycan (GAG) chains. GAGs are extremely diverse due to the number of ways 
that they can be altered, including addition of sulfate moieties [15,16]. Chondroitin sulfate/dermatan 
sulfate side chains are associated with decorin and biglycan, while keratan side chains are associated 
with  lumican  [17,18].  In  addition,  heparan  sulfate  proteoglycans  are  not  detected  in  the  healthy 
uninjured cornea [19]. The knowledge of proteoglycan core regulation and GAG synthesis by two 
different cell lineages can be vital when developing corneal substitutes in vitro. 
In our study, cord stem cells deposited collagen in an aligned configuration with a mean diameter 
similar to that of collagen  in  normal  human stromas. The core proteoglycan,  perlecan,  showed an 
increase  in  mRNA  in  response  to  TGF-1,  along  with  the  presence  of  sulfated  GAGs.  The 
development of such a model using cord stem cells may provide an alternative source of tissue for 
corneal transplantation.  
2. Materials and Methods 
2.1. Establishment of Umbilical Cord Mesenchymal Stem Cells  
Umbilical cord mesenchymal stem cells (cord stem cells) were obtained from Dr. Biagio Saitta at 
Cedars-Sinai Medical Center/Regenerative Medicine Institute, Las Angeles, CA, and were isolated as 
previously reported [20]. Briefly, cells were harvested at birth from the placenta of full-term deliveries 
with  the  consent  of  the  parents.  This  was  done  under  the  International  Review  Board-approved 
protocol to the New Jersey Cord Blood Bank, where Saitta previously worked. Blood was collected 
within 10 min of placenta removal and was drained into a plastic bag with 25 mL of citrate phosphate 
dextrose anticoagulant solution (Medsep Corporation; Covina, CA). Cells were processed as reported 
previously  [20]  and  were  used  between  passages  5–10.  Detailed  characterization  and  expression 
markers can be found in Markov et al.’s manuscript [20]. 
2.2. Fibroblast Assembled Extracellular Matrix 
The  cord  stem  cells  were  plated  on  transwell  6-well  plates  containing  24-mm  polycarbonate 
membrane inserts with 0.4 m pores (Costar; Charlotte, NC) at a density of 2 × 10
6 cells in 1.5 mL 
EMEM.  The  seeding  density  was  determined  by  a  number  of  preliminary  experiments  where  the 
amount of extracellular matrix deposited was the critical element. Constructs were allowed to grow for 
4 weeks in either VitC media—EMEM with 10% FBS and 0.5 mM 2-O--D-glucopyranosyl-L-ascorbic 
acid (VitC: Wako Chemicals USA, Inc.; Richmond, V.A.)—only (control), or VitC media + 0.1 ng/mL 
TGF-1 (TGF-1 treated). Preliminary concentration-dependent experiments with TGF-1 ruled out 
higher concentrations of the growth factor due to construct contraction. At week 4, samples of the 
resulting constructs were collected and processed for immunofluorescence microscopy, transmission 
electron microscopy (TEM) and Real Time RT-PCR.  
2.3. Thickness 
Constructs  were  fixed  in  4%  paraformaldehyde  and  processed  for  immunofluorescence,  as 
previously  described  [21,22].  Constructs  were  stained  with  phalloidin-rhodamine  (Invitrogen; J. Funct. Biomater. 2011, 2                             
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Carlsbad, CA, USA), which binds and stains the f-actin filaments and allows for the visualization of all 
cells within the construct. Also, TOPRO-3 iodide (Invitrogen) was used to stain the cell nuclei. The 
constructs were imaged on a TCS-SP2 confocal microscope (Leica Microsystems; Bannockburn, I.L., 
UK).  The  total  thickness  of  the  constructs  was  calculated  using  the  confocal  z-series,  where  we 
measured  from  the  very  top  cell  to the  very  bottom  one.  To obtain  a  visual  confirmation  of  this 
measurement, orthogonal  sections  of  the  same  confocal  z-series  were  created  with  the  Image  Pro  
Plus software.  
2.4. Transmission Electron Microscopy  
At 4 weeks, the constructs were fixed in ½ strength Karnovsky’s fixative (2% paraformaldehyde, 
2.5%  glutaraldehyde  in  cacodylate  buffer,  pH  7.4)  and  processed,  as  previously  described  [23]. 
Briefly,  samples  were  cut  transversely  to  the  plane  of  the  construct,  using  a  diamond  knife 
ultramicrotome  (LKB  ultramicrotome;  Bromma,  Sweden).  Sections  (60–90  Å)  were  obtained, 
examined and photographed with a Philips 410 Transmission Electron Microscope (Philips Electronics 
N.V.; Eindhoven, The Netherlands) equipped with a digital camera.  
2.5. Cell Numbers and Matrix Production 
Using Image Pro Plus (v.7: Media Cybernetics; Bethesda, MD, USA), we quantified the total cell 
number per construct per condition, as well as, cell per unit volume. A minimum of 3 confocal z-series 
was used for each condition, and their average was plotted and analyzed. 
2.6. Real Time RT-PCR  
Total RNA was extracted using the RNeasy kit (Qiagen; Valencia, CA, USA). Genomic DNA was 
removed by incubation with RNase-free DNase I (M0303S: New England BioLabs; Ipswich, MA, 
UK) in the presence of RNase inhibitor. The RNA was annealed with random hexamer and oligo-dt 
primers, and first strand synthesis was carried out with MuLV reverse transcriptase. Negative controls 
were  performed  without  reverse  transcriptase.  Real-Time  PCR  was  performed  on  an  Applied 
Biosystems 7300 Real-Time PCR system (Foster City, CA, USA) using ABI TaqMan human gene 
expression  assays  for  perlecan  (Hs01078536.m1),  keratocan  (Hs00559942.m1),  decorin 
(Hs00370384.m1),  lumican  (Hs00158940.m1),  collagen  1A1  (Hs00164004.m1),  collagen  5A1 
(Hs00619088.m1), and the eukaryotic 18S rRNA endogenous control (4308329), which was used for 
normalization. The cycling parameters were as follows: 50 °C for 2 min, 95 °C for 10 min, 40 cycles 
of 95 °C for 15 s and 60 °C for 1 min. Calculations were carried out using the Ct method of relative 
quantitation. Results were expressed as the mean of relative mRNA levels ± SEM. 
2.7. Cuprolinic Blue Staining and GAG Side Chain Measurements 
Cuprolinic blue is an electron-dense reagent which has been shown to identify sulfated GAGs and 
to  demonstrate  the  association  of  sulfated  GAGs  with  matrix  molecules,  such  as  collagen  [24].  
The  length  of  cuprolinic  blue  stained  filaments indicates  the  extent of  their  sulfation.  Briefly,  the J. Funct. Biomater. 2011, 2                             
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samples were stained with 0.2% Cuprolinic blue (in buffer containing 0.3 M MgCl2) for 24 hours, 
dehydrated and processed for electron microscopy [25-27].  
One  hundred  cuprolinic  blue  stained  GAG  side  chains  were  randomly  chosen  from  each  
region—apical, middle and basal—of each construct, and their length were measured using ImageJ 
v.1.5  [28].  Results  were  analyzed  for  significance  (p  <  0.05)  and  plotted  (Prism  v.5.0:  GraphPad 
Software, Inc.; La Jolla, CA, USA) [27]. 
2.8. Collagen Fibril Diameter Measurements 
Fibril  diameters  for  each  condition  were  measured  and  compared  using  Photoshop  (v.10.0.1).  
The scale bar for the TEM was used to calibrate the measurements. At least ten randomly chosen 
electron micrographs were used for each condition and a total of more than 100 fibrils were measured. 
Results were plotted and analyzed for significance (p < 0.05). 
2.9. Statistical Analysis 
All experiments were repeated at least three times and data was analyzed for significant variations 
(p < 0.05) using the Student’s t-test and Dunnett’s Multiple Comparison test.  
3. Results 
3.1. Construct Characterization 
In our previous work [21,22,29], we have shown that corneal fibroblasts have the ability to secrete 
and lay down a fibrous collagen extracellular matrix in the presence of derivatized VitC. We have 
demonstrated  the  effect  of  TGF-1,  -2  and  -3  in  these  cultures  [22].  In  the  current  study,  we 
examined the ability of cord stem cells to synthesize a matrix in the presence of VitC ± TGF-1. The 
development of an extracellular matrix in vitro would be useful for many applications in stem cell 
tissue engineering. 
After  4  weeks,  cord  stem  cells  cultured  in  the  presence  of  VitC  resulted  in  a  construct 
approximately 35 m thick, which is similar to constructs synthesized by human corneal fibroblasts 
under the same conditions (Figure 1.1 and 1.2A, C) [21,22]. Surprisingly, when TGF-1 was added to 
the cord stem cell cultures, no significant increase was found in the construct thickness (Figure 1.1 and 
1.2D). This is in contrast to constructs synthesized by human corneal fibroblasts, where the thickness 
increased  2–3  fold  (p  <  0.0001;  Figure  1.1  and  1.2A,  B).  Results  were  confirmed  and  shown  in  
Figure 1.2 using orthogonal sections created with Image Pro Plus software. This data suggests that a 
differential path of expression may exist between the two cell types.  J. Funct. Biomater. 2011, 2                             
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Figure  1.  Total  construct  thickness  for  Control  and  TGF-1  treated  human  corneal 
fibroblasts and cord stem cells. (1) Graphical representation of construct thickness. Note 
that  human  corneal  fibroblast  constructs’  thickness  was  significantly  increased  when 
stimulated  with  TGF-1  (p  <  0.0001),  whereas  cord  stem  cells  showed  no  significant 
changes between Control and TGF-1 treatment; (2) Orthogonal view of constructs after 3D 
reconstruction of images captured by confocal microscopy with a 40x objective; (2A and B) 
Human corneal fibroblast constructs, Control and TGF-1, respectively; and (2C and D) 
Cord stem cells, Control and TGF-1, respectively. Red = Phalloidin, Blue = TOPRO-3. 
 
3.2. Ultrastructural Studies 
Cell-matrix  interactions  revealed  similarities  between  the  two  cell  lineages.  Cord  stem  cells 
assembled aligned collagen that alternated directions in Controls (Figure 2A). When stimulated with 
TGF-1 (Figure 2B), the number of alternating layers appeared to decrease resulting in a higher degree 
of alignment. This observation was similar to what was seen previously with corneal fibroblasts [21]. 
Also, in the cord stem cell constructs, cells were elongated and very similar in morphology to human 
corneal fibroblasts (data not shown), with the addition of TGF-1, these cells resulted in more aligned 
actin-like filaments, indicative of myofibroblasts (data not shown). Vesicles were also seen under both 
conditions (Figure 2); however, they were more abundant when constructs were treated with TGF-1 
(Figure  2B).  Vesicles  were  recently  identified  by  us  and  reported  as  a  potential  myofibroblast  
marker [22].  J. Funct. Biomater. 2011, 2                             
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Figure  2.  TEM  (31,000×)  showing  cell-matrix  interaction  of  cord  stem  cells  in  two 
different  conditions:  (A)  Control  and  (B)  TGF-1  treated.  Note:  Fibril  (F)  alignment 
alternated direction in control and to a much lesser extent in TGF-1 treated; however, 
TGF-1 treatment (B) showed higher fibril density and more alignment than Control (A). 
C = cord stem cells. An example of a cell with vesicles (V) is shown in both A and B, 
indicating  the  presence  of  myofibroblasts  in  both  conditions  with  more  of  these  cells 
present in B. Bar = 0.5 microns. 
 
3.3. Cell Numbers and Extracellular Matrix Production 
For each sample, the cell number and the resulting cell number per unit volume were calculated 
using Image Pro Plus. When cells were stimulated with TGF-1, human corneal fibroblast constructs 
had  a  higher  total  number  of  cells  (~3  fold)  compared  to  cord  stem  cell  constructs  (p  <  0.0001;  
Figure 3A). However, there was no difference in the control groups for either lineage. Taking into 
account that the control construct thickness for both cell lineages was approximately equal, and only the 
thickness of the human corneal fibroblast construct increased with the addition of TGF-1 (Figure 1), we 
calculated the cell  number per unit volume  for all conditions. The data showed that there was no 
difference in the cell number per unit volume between control and TGF-1 stimulated cord stem cell 
constructs (Figure 3B). However, human corneal fibroblast constructs increased in cell number per unit 
volume upon TGF-1 stimulation (Figure 3B). Human corneal fibroblasts showed significantly higher 
numbers of cells per unit volume, both in Controls and TGF-1 when compared to cord stem cells  
(p < 0.001). Overall our data indicates that the cord stem cells assembled a more extensive matrix per 
cell than the human corneal fibroblasts.  J. Funct. Biomater. 2011, 2                             
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Figure 3. Graphs of the total number of cells present (A), and total number of cells per unit 
volume (mm
2) (B), within the two types of constructs. (A) In control constructs for both 
human corneal  fibroblasts and cord stem cells,  identical  number of cells was apparent; 
however, upon the addition of TGF-1, the number of cells in the human corneal fibroblast 
constructs were significantly upregulated (p < 0.0001), whereas the cord stem cell number 
remained relatively unchanged; (B) Human corneal fibroblast constructs had more cells per 
unit volume compared to cord stem cells (p < 0.001) in both control and TGF-1 treatment. 
Human corneal fibroblast cell numbers per unit volume increased slightly with TGF-1 
treatment, where cord stem cells remained unchanged. 
 
 
3.4. Collagen  
In our previous work with human corneal fibroblasts [22], we found that the Control and TGF-1 
treated construct fibril diameter means were 27 and 32 nm, respectively, which was similar to that seen 
in the mature human corneal stroma, 30–35 nm (hydrated type I/V collagen). In the present study with 
the cord stem cells, the fibril diameters in the Control constructs (Figure 4A) had a range of 15–42 nm, 
with a mean diameter of 28 nm. In response to TGF-1 (Figure 4B), the mean fibril diameter was  
32 nm, with a range of 23–60 nm. Thus, TGF-1 slightly, but significantly (p < 0.001), increased the 
mean collagen fibril diameter of the cord stem cells. The data indicates that the fibril diameters of the 
cord stem cells were similar to those seen in the human corneal fibroblast constructs and the mature 
human corneal stroma. Of note, following injury in human corneal stroma, the fibril diameter range 
was found to increase (15–65 nm) [30]. 
As  Type  I  and  V  collagen  are  known  to  be  the  major  stromal  collagens,  we  examined  their 
expression in the construct to observe if their expression was modulated by cord stem cells in the 
presence of TGF-1 (Figure 5). Collagen I (Figure 5A) mRNA was only enhanced in the constructs 
synthesized by human corneal fibroblasts (p < 0.005). We found that TGF-1 enhanced the Collagen 
V mRNA expression (Figure 5B) in both cell lineages (p < 0.05), indicating that the constructs both 
showed a response to changes in extracellular matrix independent of the cell/matrix density.  
 J. Funct. Biomater. 2011, 2                             
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Figure  4.  Histograms  demonstrating  the  distribution  of  cord  stem  cell  construct  fibril 
diameters under two conditions: (A) Control and (B) TGF-1 treated. (A) Control fibril 
diameters ranged from 15 to 42 nm with a mean diameter at 28 nm; (B) TGF-1 showed a 
range  from  23  to  60  nm  with  mean  size  of  32  nm.  This  shift  of  fibril  diameters  was 
significantly different (p < 0.001).  
 
Figure  5.  Relative  quantification  of  Collagen  Type  I  and  V  mRNA  after  Real  Time  
RT-PCR. (A) Collagen I mRNA was significantly upregulated (p < 0.005) in the human 
corneal fibroblast constructs stimulated with TGF-1; and (B) Collagen V mRNA expression 
was significantly upregulated after TGF-1 stimulation in both cell lineages (p < 0.05). 
 
3.5. GAG Expression and Deposition 
Proteoglycans  are  known  to  play  an  important  role  in  extracellular  matrix  organization  in 
development and during pathology. Previously, in human corneal fibroblast 3D construct, the expression 
of  proteoglycan  cores  (lumican,  decorin  and  keratocan)  was  detected.  In  addition,  the  presence  of 
associated sulfated GAGs was examined throughout the depth of the construct [27]. Since the regulation 
of proteoglycans may be critical for the design of a cornea-like construct, one of the goals of this study 
was to examine the expression of proteoglycan transcripts in the cord stem cell constructs.  
The expression of proteoglycan core transcripts was performed using Real Time RT-PCR. In the 
cord stem cell constructs, there was a ~2-fold decrease in decorin and keratocan mRNA (p < 0.05) 
when  the  cultures  were  incubated  in  the  presence  of  TGF-1  (Figure  6A).  While  there  was  no 
detectable change in lumican mRNA, there was a significant increase (p < 0.05) in perlecan mRNA 
(Figure 6A). This regulation was similar to what was seen in human corneal fibroblasts (Figure 6B). 
Upon  TGF-1  treatment,  keratocan  was  downregulated  ~3-fold  (p  <  0.05),  lumican  remained 
unchanged, and decorin and perlecan both were upregulated.  J. Funct. Biomater. 2011, 2                             
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Figure 6. Real Time RT-PCR analysis of proteoglycans: lumican, keratocan, decorin, and 
perlecan.  (A)  In  the  cord  stem  cell  constructs,  perlecan  was  significantly  upregulated  
(p < 0.005) with the addition of TGF-1, and decorin and keratocan were significantly 
downregulated (p < 0.05); and (B) In the human corneal fibroblast constructs, keratocan 
was significantly downregulated (p < 0.05) with the addition of TGF-1; whereas, the 
other proteoglycans remained relatively the same, with only slight increases.  
 
 
 
The major change in response to TGF-1 in the cord stem cell constructs may be the significant 
increase  in  sulfated  GAGs.  The  presence  of  GAGs  was  analyzed  throughout  the  construct  using 
Cuprolinic Blue, which binds to sulfated moieties [24,27]. The GAG filaments were detected in either 
the plane of the collagen fibril (Figure 7.1B and D, “GAG” arrows) or associated with fibrils out of the 
plane of the image. In control constructs of both human corneal fibroblasts (Figure 7.1A) and cord 
stem cells (Figure 7.1C) the filaments are present and are ~20 nm and 30 nm, respectively (Figure 7.2). 
Upon the addition of TGF-1, the GAG filament length in the human corneal fibroblast (Figure 7.1B) 
and cord stem cell (Figure 7.1D) constructs increased significantly (p < 0.0001, Figure 7.2), indicating 
a similar mechanism of extracellular matrix organization.  J. Funct. Biomater. 2011, 2                             
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Figure  7.  GAGs  in  constructs  stained  with  cuprolinic  blue  (1)  and  length  of  GAG 
filaments quantified (2). (1) TEM of constructs stained with cuprolinic blue in order to 
visualize the GAGs in human corneal fibroblast constructs (A) Control and (B) TGF-1 
treated,  and  cord  stem  cell  constructs  (C)  Control  and  (D)  TGF-1  treated.  Note  the 
increase in the GAG length with the addition of TGF-1 to both cell lineages (B and D: 
“GAG” arrows). In addition, in both conditions, GAGs were present throughout the entire 
construct; and (2) Quantification of GAG fibril length in human corneal fibroblast and cord 
stem  cell  constructs.  GAGs  were  significantly  (p  <  0.0001)  increased  in  length  when  
TGF-1 was present in both cell lineages. 
 
4. Discussion 
The potential for developing cornea-like biomaterials has been greatly advanced with the use and 
availability  of  stem  cells.  The  unique  ability  of  stem  cells  to  differentiate  and  adapt  to  various 
environments is on the verge of improving tissue integrity and stability following injury/trauma. They 
have been associated with repair of many organs [31-33], and researchers [2,3] have shown that stem 
cells contribute to the regeneration of a variety of tissues, such as bone, cartilage, muscle, ligament, 
tendon, adipose and stroma. They can be detected in various adult tissues, such as bone marrow [34], 
skin [35,36], retina [37], and corneal endothelium [38,39], and can now be isolated and purified using 
specific surface markers [40-42].  
The present study demonstrates the ability of the cord stem cells to secrete and organize their own 
extracellular matrix under conditions similar to those needed by the human corneal fibroblasts [21,22,27]. 
The extracellular matrix produced by the cord stem cells expressed mRNA transcripts of Type I and V 
collagen as did the human corneal fibroblasts, and the fibril diameters were not significantly different 
from  human corneal stromas [43].  This  is a demonstration that the stem cells show the ability to 
differentiate and synthesize a stroma-like matrix. Healthy human corneal stroma is known to contain 
type  I  and  V  collagen  heteromers  at  a  ratio  of  85:15,  which  is  thought  to  play  a  major  role  in 
maintaining fibril diameters [44]. Our data suggests that cord stem cells could potentially be used as an 
alternative to human corneal fibroblasts, with a potentially longer life span and minimum, to no risks for 
the host tissue/organ. This is in agreement with recent findings by Liu and coworkers [45], where they 
reported that cord stem cells do not raise the immune response when transplanted into mouse corneas. J. Funct. Biomater. 2011, 2                             
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One of the most striking aspects of our study was the apparent increase in alignment of the fibrils 
upon TGF-1 stimulation of the cord stem cells. The mechanisms involved in collagen fibril alignment 
are controversial and a more comprehensive discussion is found in the review by Ruberti and Zieske 
(2008) [46]. In general, several mechanisms have been postulated including template direction, cell 
guidance, and intrinsic properties of the collagen. Our data, which indicate that both corneal fibroblasts 
and cord stem cells have the ability to secrete aligned collagen, suggests that alignment is not a unique 
property  of  corneal  cells.  Rather,  the  concentration  and  composition  of  the  secreted  collagen  and 
proteoglycans  might  direct the  alignment.  Our data  showing  the  increased  sulfation  with  TGF-1 
stimulation may be relevant to this possibility.  
Cord  stem  cells  share  most  of  their  immunophenotype  with  MSCs,  including  a  cluster  of 
differentiating markers, neural markers and extracellular adhesion molecules, as reviewed by Cao and 
Feng [47]. Briefly, cord stem cells were found negative for CD14, CD28, CD31, CD33, CD34, CD45, 
CD56, CD133, and HLA-DR, which makes them a good candidate for transplantation without raising 
immune responses. Their potential as biomaterials and their availability for transplantation has been 
exploited recently with promising results. Cord stem cells are already widely accepted as a source of 
hematopoietic  stem  and  progenitor  cells,  and  transplants  have  been  performed  for  various  
diseases [48]. Other investigators have suggested that cord stem cells may differentiate both in vitro 
and in vivo into a variety of different cell lineages. Baksh et al. [49] assessed the potential of human 
umbilical cord stem cells, they found that the cord stem cells were equal or superior to the hBMSCs, 
showing higher proliferative potential, as well as higher capability of osteogenic, chondrogenic and 
adipogenic differentiation. Recently, Wang et al. [50] showed the benefits of using cord stem cells in a  
tissue-engineering model. The authors reported higher adherence of the cord stem cells to polyglycolic 
acid  scaffolds  compared  to  hBMSCs.  More  importantly  they  found  a  2-fold  increase  in  collagen 
production. In our present study, we show that these cells have at least equivalent capabilities as the 
human corneal fibroblasts to create an extracellular matrix that can be used as a carrier or a biomaterial 
in wounded corneas.  
The  other  major  structural  components  that  are  important  for  corneal  development  are  the 
proteoglycans. These proteoglycans contain chondroitin or keratan sulfate side chains that associate 
with collagen fibrils, and are known to change during corneal development [51-53] and response to 
injury  [18,19,54].  After  injury  several  modifications  to  proteoglycans  are  observed,  including  the 
expression of proteoglycans with heparan sulfate side chains, and modification of other side chains, 
resulting in an increase in dermatan sulfate [18,19,54]. 
Liu  et  al.  [45]  successfully  transplanted  cord  stem  cells  to  Lum
-/-  mice,  improving  corneal 
transparency  and  stromal  thickness,  as  well  as  showing  expression  of  keratocyte  specific 
proteoglycans, such as keratocan and lumican. The study proposed that survival of these cells in mouse 
corneas indicated that they would also be accepted in human hosts. Our data suggest that our culture 
conditions containing high levels of VitC may mimic the inductive properties of the adult stroma. 
Du and coworkers [55], isolated stem cells from human corneas and injected them into mice in 
order to investigate stromal opacity. They found that corneal transparency in the treated mice was 
indistinguishable from that of untreated mice, suggesting immune privilege of adult stem cells and the 
ability to regenerate tissue. Again, corneal specific proteoglycans were expressed, indicating their vital 
role to the cornea‘s transparency and integrity. We have previously demonstrated that the core proteins J. Funct. Biomater. 2011, 2                             
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were synthesized and expressed by our 3D in vitro corneal fibroblasts model, and that the collagen 
fibrils displayed associated sulfated GAGs [27]. When the cord stem cells were placed into this model, 
the core proteins were also expressed. This further supports the potential of inducing these cells to 
produce a biomimetic cornea. 
A potential problem with some of the studies listed above is that they involve the injection of the 
cells into a potentially compromised setting. This could be even more problematic in the case of an 
injury or disease where a portion of the cornea is degraded or even missing. Our studies suggest that it 
may be possible to grow a stroma-like tissue using cord stem cells that could be transplanted into the 
wound area, thus providing a scaffold for repair. 
We are also intrigued by the TGF-1-stimulated cord stem cells results, which were somewhat 
surprising. With human corneal fibroblasts, TGF-1 appeared to stimulate fibrosis; however, with cord 
stem cells, TGF-1 actually appeared to assemble a more aligned matrix. In addition, we found an 
increase in perlecan, similar to that seen in corneal fibroblasts [19,56]. While, there is no increase in 
the overall thickness of the construct with TGF-1, there is a significant increase in the number of 
GAGs  along  the  collagen  fibrils  and  in  the  length of  the  GAGs,  all  of  which  are  indicative  of  a 
developmental phenotype. In addition, the size of the Cuprolinic blue filaments was similar to those 
reported for the human corneal stroma [57]. Also, the increase in filaments along the collagen fibrils 
has also been reported in early reports by Cintron et al. [17] in wounded rabbit corneal stomas.  
5. Conclusions 
Cord stem cells have the capability of differentiating into other cell types, as well as being readily 
available  without  any  host-rejection  concerns.  Our  3D  model  data  shows  that  these  cells  can  be 
stimulated to secrete a matrix similar to the one secreted by human corneal fibroblasts. Further studies 
are underway in order to characterize these cells in vitro, as well as in a cornea environment in vivo. 
Overall, cord stem cells hold great promise as a substitute for corneal transplants. 
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